Cardiff Oncology Inc to Discuss Updated Data from Lead Clinical Program in KRAS-mutated Metastatic Colorectal Cancer at ASCO-GI Transcript
Good afternoon, and welcome to the Cardiff Oncology Data Presentation Webcast. (Operator Instructions). Please be advised that this call is being recorded at the company's request, and a replay will be available on the company's website. I would now like to turn the call over to Tom Galassi of LifeSci Advisors. Please go ahead.
Thank you, operator, and thank you all for participating in today's conference call. Before we start, I'd like to point out that the slides referenced by management on today's call will be broadcast on the webcast system or for those of you who have dialed in by phone, you can download the webcast slides from the Cardiff Oncology homepage. I'd also like to remind all listening that certain statements in this presentation are forward-looking within the meaning of the Private Litigation Reform Act of 1995 as disclosed on the slide. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements and investors should read the risk factors set forth on the
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |